-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Tongyuankang Pharmaceutical-B (02410.HK) issued an announcement. As announced by the company on August 27, 2026, the new drug Kadasha (TY-9591) independently developed by the company has been approved by the China National Drug Administration for first-line adult patients with epidermal growth factor receptor (EGFR) exon 19 deficiency (19DEL) or exon 21 (L858R) replacement mutations, accompanied by locally advanced or metastatic non-small cell lung cancer (NSCLC) metastases in the central nervous system (CNS) treatment.

Zhitongcaijing·11/11/2026 12:33:49
Listen to the news
Zhitong Finance App News, Tongyuankang Pharmaceutical-B (02410.HK) issued an announcement. As announced by the company on August 27, 2026, the new drug Kadasha (TY-9591) independently developed by the company has been approved by the China National Drug Administration for first-line adult patients with epidermal growth factor receptor (EGFR) exon 19 deficiency (19DEL) or exon 21 (L858R) replacement mutations, accompanied by locally advanced or metastatic non-small cell lung cancer (NSCLC) metastases in the central nervous system (CNS) treatment.